Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions.

Clavel C, Cucherousset J, Lorenzato M, Caudroy S, Nou JM, Nazeyrollas P, Polette M, Bory JP, Gabriel R, Quereux C, Birembaut P.

Br J Cancer. 2004 May 4;90(9):1803-8.

2.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

3.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
4.
5.

Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions.

Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC.

Cancer Cytopathol. 2011 Aug 25;119(4):228-34. doi: 10.1002/cncy.20172. Epub 2011 Jul 5.

6.

Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.

Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P.

Br J Cancer. 2001 Jun 15;84(12):1616-23.

7.

[Human papillomavirus typing in routine cervical smears. Results from a series of 3778 patients].

Levert M, Clavel C, Graesslin O, Masure M, Birembaut P, Quereux C, Gabriel R.

Gynecol Obstet Fertil. 2000 Oct;28(10):722-8. French.

PMID:
11244634
8.

Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study.

Dalstein V, Riethmuller D, Prétet JL, Le Bail Carval K, Sautière JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C.

Int J Cancer. 2003 Sep 1;106(3):396-403.

9.

Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.

Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P.

Obstet Gynecol. 2007 Jun;109(6):1325-31.

PMID:
17540804
10.

HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.

Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A.

JAMA. 2000 Jan 5;283(1):81-6.

PMID:
10632284
12.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
13.

Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.

Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, Howard M, Chong S, Daya D, Chapman W, Chernesky M.

CMAJ. 2000 Sep 5;163(5):513-8.

14.

The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.

Recio FO, Sahai Srivastava BI, Wong C, Hempling RE, Eltabbakh GH, Piver MS.

Eur J Gynaecol Oncol. 1998;19(3):203-8.

PMID:
9641214
15.

Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions.

Clavel C, Masure M, Levert M, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P.

Diagn Mol Pathol. 2000 Sep;9(3):145-50.

PMID:
10976721
16.

High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age.

Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS.

J Reprod Med. 2000 Apr;45(4):345-50.

PMID:
10804494
17.

Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.

Pan QJ, Hu SY, Guo HQ, Zhang WH, Zhang X, Chen W, Cao J, Jiang Y, Zhao FH, Qiao YL.

Gynecol Oncol. 2014 May;133(2):172-9. doi: 10.1016/j.ygyno.2014.03.008. Epub 2014 Mar 11.

PMID:
24631450
18.

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.

Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J.

J Natl Cancer Inst. 2004 Feb 18;96(4):280-93.

PMID:
14970277
19.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
20.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

Supplemental Content

Support Center